{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:48:20Z","timestamp":1785815300339,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-024-04004-4","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T02:51:46Z","timestamp":1735613506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reversible cerebral vasoconstriction syndrome in a methylphenidate-treated patient: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Marie-No\u00eblle","family":"Osmont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Malrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Ruellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Benchikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Herlem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie-Marie","family":"Scailteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"10","key":"4004_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S1474-4422(12)70135-7","volume":"11","author":"A Ducros","year":"2012","unstructured":"Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11(10):906\u201317.","journal-title":"Lancet Neurol"},{"issue":"8","key":"4004_CR2","first-page":"886","volume":"72","author":"G Delannoy","year":"2022","unstructured":"Delannoy G, Gazzola S. Syndrome de vasoconstriction c\u00e9r\u00e9brale r\u00e9versible [Reversible cerebral vasoconstriction syndrome]. Rev Prat. 2022;72(8):886.","journal-title":"Rev Prat"},{"issue":"3","key":"4004_CR3","doi-asserted-by":"publisher","first-page":"e241349","DOI":"10.1001\/jamanetworkopen.2024.1349","volume":"7","author":"M Garcia-Argibay","year":"2024","unstructured":"Garcia-Argibay M, B\u00fcrkner PC, Lichtenstein P, Zhang L, D\u2019Onofrio BM, Andell P, Chang Z, Cortese S, Larsson H. Methylphenidate and Short-Term Cardiovascular Risk. JAMA Netw Open. 2024;7(3):e241349.","journal-title":"JAMA Netw Open"},{"key":"4004_CR4","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2013 Ritaline 10 mg mg, g\u00e9lule.\u00a0https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=60059081&typedoc=R. Accessed 23 July 2024."},{"issue":"9","key":"4004_CR5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph16091292","volume":"16","author":"R Bie\u015b","year":"2023","unstructured":"Bie\u015b R, Fojcik J, Warchala A, Tr\u0119dzbor B, Krysta K, Piekarska-Bugiel K, Krzystanek M. The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals (Basel). 2023;16(9):1292.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"4004_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/088307380001500414","volume":"15","author":"A Schteinschnaider","year":"2000","unstructured":"Schteinschnaider A, Plaghos LL, Garbugino S, Riveros D, Lazarowski A, Intruvini S, Massaro M. Cerebral arteritis following methylphenidate use. J Child Neurol. 2000Apr;15(4):265\u20137.","journal-title":"J Child Neurol"},{"issue":"1","key":"4004_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/15622970510029966","volume":"7","author":"G Thomalla","year":"2006","unstructured":"Thomalla G, Kucinski T, Weiller C, R\u00f6ther J. Cerebral vasculitis following oral methylphenidate intake in an adult: a case report. World J Biol Psychiatry. 2006;7(1):56\u20138.","journal-title":"World J Biol Psychiatry"},{"issue":"9","key":"4004_CR8","first-page":"3519","volume":"25","author":"TJ Song","year":"2021","unstructured":"Song TJ, Lee KH, Li H, Kim JY, Chang K, Kim SH, Han KH, Kim BY, Kronbichler A, Ducros A, Koyanagi A, Jacob L, Kim MS, Yon DK, Lee SW, Yang JM, Hong SH, Ghayda RA, Kang JW, Shin JI, Smith L. Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review. Eur Rev Med Pharmacol Sci. 2021;25(9):3519\u201329.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"4004_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pediatrneurol.2013.05.005","volume":"49","author":"Bain","year":"2013","unstructured":"Bain, et al. Call-Fleming syndrome: headache in a 16-year-old girl. Pediatr Neurol. 2013;49(2):130-133.e1.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"4004_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"6","key":"4004_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"4004_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","volume":"74","author":"N Moore","year":"2019","unstructured":"Moore N, Berda\u00ef D, Blin P, Droz C. Pharmacovigilance - The next chapter. Therapie. 2019;74(6):557\u201367.","journal-title":"Therapie"},{"issue":"4","key":"4004_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.neurol.2009.07.019","volume":"166","author":"A Ducros","year":"2010","unstructured":"Le DA. syndrome de vasoconstriction c\u00e9r\u00e9brale r\u00e9versible [Reversible cerebral vasoconstriction syndrome]. Rev Neurol (Paris). 2010;166(4):365\u201376.","journal-title":"Rev Neurol (Paris)"},{"issue":"6","key":"4004_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/0333102416650706","volume":"37","author":"MA Topcuoglu","year":"2017","unstructured":"Topcuoglu MA, Chan ST, Silva GS, Smith EE, Kwong KK, Singhal AB. Cerebral vasomotor reactivity in reversible cerebral vasoconstriction syndrome. Cephalalgia. 2017;37(6):541\u20137.","journal-title":"Cephalalgia"},{"key":"4004_CR15","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Rapport d\u2019\u00e9valuation des sp\u00e9cialit\u00e9s \u00e0 base de m\u00e9thylph\u00e9nidate (Avis d\u00e9finitif modifi\u00e9 le 31\/03\/2021). \nhttps:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-09\/rapport_reevaluation_methylphenidate_avisdef_cteval485.pdf.\u00a0Accessed 18 Oct 2024."},{"key":"4004_CR16","unstructured":"\ufeffDirective 2010\/84\/UE du Parlement europ\u00e9en et du Conseil du 15 d\u00e9cembre 2010 modifiant, en ce qui concerne la pharmacovigilance, la directive 2001\/83\/CE instituant un code communautaire relatif aux m\u00e9dicaments \u00e0 usage humain \u2013 L\u00e9gifrance, 2010. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000023365000. (Accessed 21 Oct 2024)."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04004-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-04004-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04004-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:19:11Z","timestamp":1735658351000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-04004-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4004"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-04004-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The use of patients\u2019 personal and clinical data is authorized by a European Directive that states that pharmacovigilance systems should use all appropriate measures to obtain accurate, verifiable information for the scientific evaluation of suspected adverse reaction reports, including reidentification of records identifying ADRs []. MNO, LMS, ALR, AB, EH and EP are members of the regional pharmacovigilance centres, an integral part of the French national pharmacovigilance system under the aegis of the French Medicine Agency ANSM.Written informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"494"}}